- Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon
- Tarsus to Participate at Upcoming Investor Conferences
- Tarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis
- Tarsus Announces Pricing of $100.0 Million Public Offering
- Tarsus Announces Proposed $100.0 Million Public Offering
- Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements
- Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept “Tick-Kill” Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease
- Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024
- Tarsus to Participate in Fireside Chat at the Sixth Annual Guggenheim Healthcare Talks Conference
- Tarsus Announces Positive Topline Results from the Ersa Phase 2a Clinical Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease in Patients with Demodex Mites
More ▼
Key statistics
On Friday, Tarsus Pharmaceuticals Inc (TARS:NSQ) closed at 32.04, -20.69% below its 52-week high of 40.40, set on Feb 28, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 32.57 |
---|---|
High | 33.21 |
Low | 31.26 |
Bid | 29.39 |
Offer | 39.60 |
Previous close | 32.21 |
Average volume | 367.79k |
---|---|
Shares outstanding | 37.49m |
Free float | 34.60m |
P/E (TTM) | -- |
Market cap | 1.20bn USD |
EPS (TTM) | -4.58 USD |
Data delayed at least 15 minutes, as of Apr 26 2024 21:00 BST.
More ▼